Rigin Limited Evidence

What It Is

Rigin is the trade name, owned by Sederma (a subsidiary of Croda International), for the cosmetic active ingredient palmitoyl tetrapeptide-7 — a synthetic lipopeptide consisting of a four-residue peptide sequence (glycyl-glutaminyl-prolyl-arginine, Gly-Gln-Pro-Arg, GQPR) covalently coupled at the N-terminus to a sixteen-carbon saturated palmitic acid chain. The parent GQPR sequence corresponds to residues 224–227 of the hinge region of the human immunoglobulin G (IgG) heavy chain — a region of the antibody molecule that is exposed following immunoglobulin cleavage and that has been studied for several decades as the origin of a family of small immunomodulatory peptides (the "tuftsin family"). The palmitoyl moiety increases the molecule's lipophilicity and is the standard Sederma approach to improving stratum corneum penetration of an otherwise polar peptide.

The compound is assigned INCI name "Palmitoyl Tetrapeptide-7." An older INCI designation for the identical molecule — "Palmitoyl Tetrapeptide-3" — persists on product labels predating the Personal Care Products Council (PCPC) INCI renumbering. Finished cosmetic formulations may list either name, or both, depending on label vintage. The molecular weight is approximately 692 daltons, the CAS registry number is 221227-05-0, and the material is typically supplied as a clear glycol-based solution at low-percentage concentration (Sederma's standard Rigin raw material specification is a solution delivering a fixed percentage of active peptide in butylene glycol and water). Finished-product inclusion rates are typically 2–4% of the solubilized raw material in anti-aging creams and serums, which corresponds to vanishingly small milligram quantities of the peptide in a consumer tub.

Rigin is positioned in the Sederma catalogue as an "immunomodulating anti-inflammaging" peptide — distinct in mechanism from the firm's signal peptide Matrixyl® (palmitoyl pentapeptide-4 / pal-KTTKS), which is positioned as a pro-collagen signal peptide, and from Matrixyl synthe'6® (palmitoyl tripeptide-38), a later-generation signal peptide. Commercially, Rigin's most prominent role is as one of two peptides in Matrixyl® 3000 — a 1:1 combination of palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR) that Sederma markets as a complementary extracellular-matrix duo: palmitoyl tripeptide-1 as the pro-synthesis signal and palmitoyl tetrapeptide-7 as the anti-degradation / cytokine-attenuating partner. Matrixyl 3000 is one of the most widely used peptide complexes in mid- and upper-tier topical anti-aging skincare worldwide.

The intellectual framework the manufacturer uses to describe Rigin leans on two parallel biology traditions. The first is the longstanding literature on "tuftsin" and "rigin" as naturally occurring tetrapeptides liberated from IgG proteolysis that stimulate phagocyte activation and modulate cytokine signaling — a body of work going back to the 1970s and well summarized by Rocchi and colleagues in their synthesis and biological characterization of tuftsin and rigin analogues. The second is the "inflammaging" framework popularized by Franceschi and collaborators — the hypothesis that low-grade chronic elevation of pro-inflammatory cytokines, particularly IL-6, drives age-related tissue dysfunction including collagen degradation in the skin. The Sederma positioning unifies these two traditions into a single marketing claim: an IgG-hinge-derived peptide that, topically, attenuates IL-6 secretion in the dermis and thereby protects the collagen-elastin matrix from cytokine-driven degradation. The underlying in-vitro signal is real; the leap from that signal to finished-product wrinkle claims is substantial, and is the basis of the "Limited Evidence" badge applied to this profile.

Mechanism of Action

Rigin's mechanistic claims are built from manufacturer in-vitro data plus a body of older IgG-hinge-peptide literature. The specifics below should be read as the peptide's positioning statement — biologically plausible, grounded in in-vitro work, and not independently replicated at finished-product level.

• IL-6 attenuation in cultured skin cells — Sederma's technical documentation and third-party academic summaries describe dose-dependent suppression of basal and stimulated interleukin-6 (IL-6) secretion from human keratinocyte and fibroblast cultures exposed to palmitoyl tetrapeptide-7. IL-6 is one of the central cytokines in the "inflammaging" cascade and a validated marker of cellular senescence in dermal fibroblasts; chronic elevated IL-6 is mechanistically implicated in collagen matrix turnover through induction of matrix metalloproteinases and suppression of procollagen synthesis.
• UVB-induced inflammation attenuation — In-vitro studies referenced by ingredient reviewers describe palmitoyl tetrapeptide-7 reducing the inflammatory response of keratinocyte cultures exposed to ultraviolet-B (UVB) radiation, with attenuation of downstream pro-inflammatory cytokine release. This is the mechanistic basis for the "after-sun recovery" positioning of some Rigin-containing formulations.
• Laminin and collagen VII stimulation — Manufacturer-referenced in-vitro data describe stimulation of dermal-epidermal junction proteins (laminin-IV, laminin-V) and anchoring fibril collagen (collagen VII) in cultured skin models. The biological plausibility is coherent with the peptide's positioning around the papillary dermis; the claim has not been independently replicated in an academic publication for isolated palmitoyl tetrapeptide-7.
• NF-κB pathway modulation (speculative) — IL-6 transcription in keratinocytes and fibroblasts is under strong regulation by the NF-κB transcription factor complex. The Sederma mechanistic narrative implicitly invokes NF-κB-axis modulation as the proximate signaling explanation for observed IL-6 attenuation, though the specific upstream target of the GQPR tetrapeptide has not been publicly identified. Anyone citing "NF-κB inhibition" as a Rigin mechanism is extrapolating — the downstream cytokine readout is the measured endpoint, and the specific receptor or effector through which pal-GQPR acts remains uncharacterized in peer-reviewed literature.
• Tuftsin-like phagocyte activation — The parent GQPR sequence has historically been characterized as "rigin" — a natural IgG-derived tetrapeptide first described in the 1970s tuftsin literature as a stimulator of macrophage phagocytosis and antigen-presenting cell activation. Sederma references this lineage to support broader "defense mechanism stimulation" claims for the palmitoylated analogue, though the extrapolation from naked-peptide phagocyte assays to topical stratum-corneum exposure is substantial.
• Palmitoylation for stratum corneum penetration — The sixteen-carbon palmitic acid chain is the standard Sederma penetration-enhancement strategy. Lipidation increases partition coefficient, allowing the otherwise hydrophilic GQPR peptide to traverse the lipid-rich stratum corneum extracellular matrix and reach the viable epidermis and papillary dermis where fibroblasts and keratinocytes reside. Radiolabeled penetration studies of palmitoylated peptide analogues have demonstrated measurable transport through human and porcine skin models in ex-vivo Franz cell preparations.
• Stability versus naked GQPR — The palmitoylated form is substantially more stable in cosmetic formulation (pH 5–7, oil-in-water emulsions, surfactant-containing cleansers) than the naked tetrapeptide, and more resistant to skin-surface peptidases. This is a formulation-chemistry benefit rather than a pharmacological one, but it is non-trivial for a leave-on cosmetic active expected to survive shelf storage and topical application for practical periods.
• Complementarity with palmitoyl tripeptide-1 (Matrixyl 3000) — The Sederma thesis behind Matrixyl 3000 is that palmitoyl tripeptide-1 (pal-GHK) provides a pro-synthesis signal to fibroblasts (collagen I, III, IV, VII and fibronectin upregulation through GHK-like signaling) while palmitoyl tetrapeptide-7 (pal-GQPR) provides an anti-degradation signal through cytokine attenuation. Conceptually: one peptide turns up construction, the other turns down demolition. The independent contribution of each peptide cannot be isolated from finished Matrixyl 3000 clinical data, which remains the core epistemic weakness of the combination's evidence base.
• DHEA-mimicry framing (legacy) — Older Sederma marketing literature framed palmitoyl tetrapeptide-7 as "mimicking DHEA activity" in the skin, referencing literature on age-related DHEA decline and IL-6 elevation. The analogy is rhetorical rather than mechanistic — there is no evidence that pal-GQPR engages androgen or steroid receptors, and the DHEA-mimic framing has been largely retired from modern product positioning in favor of the cleaner "IL-6 attenuation / anti-inflammaging" claim.

What the Research Shows

The evidence base for Rigin / palmitoyl tetrapeptide-7 is unusually thin for a widely distributed cosmetic active. The ingredient has been in cosmetic circulation for roughly two decades and appears in hundreds of finished products worldwide, yet the peer-reviewed publication record specifically on the isolated peptide is dominated by manufacturer-supplied data, industry conference abstracts, and ingredient-review articles that reference those sources. What follows is the honest shape of the evidence.

• Manufacturer in-vitro data — Sederma's internal technical documentation (brochures and cosmetics-industry conference presentations) contains the core IL-6 attenuation and laminin / collagen VII stimulation data. These data are consistent across the multiple ingredient-review articles that cite them (Schagen 2017, Ferreira et al. 2021), but the underlying experiments were performed and analyzed by the manufacturer and have not been independently replicated in an adversarial peer-reviewed publication.
• Ingredient-review academic literature — Several review articles in the cosmetic-dermatology literature describe palmitoyl tetrapeptide-7's positioning and claimed mechanism. Lupo's 2005 review in Dermatologic Surgery (PMID 16029675) is the most widely cited early academic summary of cosmeceutical peptides including the palmitoyl-conjugate class. Schagen's 2017 open-access review in Cosmetics (MDPI; doi 10.3390/cosmetics4020016) is a more comprehensive treatment that explicitly summarizes Rigin's IL-6-attenuation positioning. Ferreira and colleagues (2021; PMID 34358128) reviewed synthetic peptide use in sensitive-skin cosmetics and summarized Rigin's mechanistic claims. These are summary articles — they catalogue manufacturer claims, they do not constitute independent clinical validation.
• Matrixyl 3000 as the closest finished-product evidence — Independent clinical evaluations of the Matrixyl 3000 combination (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) exist in the cosmetic-dermatology literature. Because these studies invariably test the combination rather than the isolated peptides, they cannot by design separate Rigin's contribution from palmitoyl tripeptide-1's. Li and colleagues' 2023 evaluation in the Journal of Cosmetic Dermatology (doi 10.1111/jocd.15849) of a multi-peptide eye serum containing 4% Matrixyl 3000 is representative of the level of evidence — a small clinical evaluation reporting anti-wrinkle benefits for a multi-active formulation, unable to attribute effect to any individual peptide.
• Pal-KTTKS as the benchmark for what a positive cosmetic peptide study looks like — Robinson and colleagues at Procter & Gamble published a peer-reviewed vehicle-controlled clinical study of the related palmitoyl pentapeptide pal-KTTKS (Matrixyl; PMID 18492182). That study — 93 women, 24 weeks, 3 ppm pal-KTTKS — reported improvements in photoaged facial skin on expert grading and image analysis. The relevant point for Rigin is contrastive: a cosmetic peptide can generate a defensible independent-or-semi-independent clinical publication, and the absence of such a study for isolated palmitoyl tetrapeptide-7 is conspicuous despite two decades of commercial availability.
• IgG-hinge and tuftsin background literature — The upstream biology of the GQPR sequence is well-characterized in the older immunology literature. Work by Rocchi and colleagues on the synthesis and biological activity of tuftsin and rigin derivatives documented phagocyte-activating and immunomodulatory properties of the naked peptides. This background establishes biological plausibility for an IgG-hinge-derived tetrapeptide having immune-modulating activity; it does not demonstrate that a palmitoylated analogue, applied topically at cosmetic concentration, produces meaningful skin benefits in humans.
• IL-6 and skin aging — the plausibility case — Independent literature robustly supports the proposition that IL-6 is a central cytokine in the aging process, both systemically and in skin-specific contexts where IL-6 elevation correlates with senescent fibroblast phenotype and altered extracellular matrix turnover. Maggio and colleagues' review of IL-6 in aging and chronic disease (PMID 16799139) is one representative source. This literature establishes that attenuating IL-6 in the skin is a defensible anti-aging target; it does not demonstrate that topical Rigin achieves that attenuation at clinically relevant concentrations in human skin.
• Topical peptide penetration — Peptide penetration of the stratum corneum is generically limited, and the palmitoyl conjugation strategy is well-documented for improving partition and transport. Reviews of topical anti-aging peptide delivery (Gorouhi & Maibach 2009, PMID 19570043; Zhang & Falla 2009, PMID 19695480) summarize the state of the art for getting peptide actives into the viable epidermis. The evidence for palmitoyl conjugates passing the stratum corneum in ex-vivo models is reasonable; the evidence that specifically palmitoyl tetrapeptide-7 reaches concentrations sufficient for the IL-6 attenuation demonstrated in cell culture is an extrapolation.
• Formulation-level synergy claims — Matrixyl 3000 proponents describe synergistic combination benefits between pal-GHK and pal-GQPR in finished cosmetics. Formulation-synergy claims at the cosmetic-industry level are typical and typically underpowered — small-n clinical evaluations on finished multi-active products are interpreted as combination evidence without the factorial design required to test synergy rigorously. This is a generic weakness of cosmetic clinical evidence, not a Rigin-specific indictment.
• Public-interest and consumer signal — Palmitoyl tetrapeptide-7 appears in cosmetic ingredient databases as a moderately common active. It is not the most prevalent cosmetic peptide (acetyl hexapeptide-8 / Argireline and palmitoyl pentapeptide-4 / Matrixyl are both more common by SKU count) but it sits in the top tier of commercially deployed lipidated peptides. Consumer-facing popularity does not validate mechanism or efficacy — it reflects distribution, marketing, and formulation convenience.

Human Data

Human data specifically on isolated Rigin / palmitoyl tetrapeptide-7 is, to a first approximation, absent from the peer-reviewed literature. This section honestly inventories what exists, what is adjacent, and what is not available.

• No independent RCT of isolated Rigin — A PubMed search for "palmitoyl tetrapeptide-7" or "palmitoyl tetrapeptide-3" or "Pal-GQPR" as a cosmetic clinical trial endpoint returns no double-blind vehicle-controlled RCT of the isolated peptide published in a peer-reviewed journal. Manufacturer brochures reference internal usage studies (typically n≈20 women, 60 days, 3% formulation) describing improvements in skin roughness, radiance, and firmness — these are not peer-reviewed and not methodologically comparable to the Robinson pal-KTTKS study.
• Matrixyl 3000 combination evaluations — The Matrixyl 3000 combination (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) has been evaluated in small finished-product studies typically conducted by manufacturers or formulators. These are not isolatable to Rigin's contribution, and most are industry-sponsored.
• Multi-peptide finished-serum clinical evaluations — Li et al., 2023 (J Cosmet Dermatol; doi 10.1111/jocd.15849), evaluated a commercial multi-peptide eye serum containing 10% Argireline (acetyl hexapeptide-8), 4% Matrixyl 3000 (palmitoyl tetrapeptide-7 + palmitoyl tripeptide-1), and 2% Eyeliss (dipeptide-2 + palmitoyl tetrapeptide-7 + hesperidin methyl chalcone). The study reported wrinkle-depth and firmness improvements versus baseline over a treatment period. The design cannot attribute effect to palmitoyl tetrapeptide-7 or to any individual active. This is the closest published "human data" the ingredient has — a multi-active finished-product evaluation in which Rigin is one of several peptides.
• Adjacent cosmetic peptide RCT — pal-KTTKS (Matrixyl) — Robinson et al., 2005 (PMID 18492182). Randomized vehicle-controlled study in 93 women, 24 weeks of twice-daily application. 3 ppm pal-KTTKS provided statistically significant improvement in appearance of lines, wrinkles, and skin tone versus vehicle on expert grading and image analysis. This is the high-water mark for independent-or-semi-independent cosmetic peptide clinical evidence, and it is for the sister compound pal-KTTKS — not for pal-GQPR.
• Adjacent cosmetic peptide publication — acetyl hexapeptide-8 (Argireline) — Blanes-Mira et al., 2002 (PMID 18498523). The foundational characterization of acetyl hexapeptide-8 with in-vitro and preliminary topical human data for wrinkle reduction. Again, this is adjacent — a different cosmetic peptide with a different mechanism — but it is a reference case for what an independent peer-reviewed cosmetic peptide evaluation looks like.
• Adjacent clinical review — peptide cosmeceuticals — Lupo, 2005 (PMID 16029675) — the most commonly cited academic review cataloguing cosmeceutical peptides including palmitoyl-conjugate signal peptides and immunomodulatory peptides. Lupo's review references manufacturer claims rather than primary RCT data for Rigin.
• IgG-derived peptide immunomodulation — Older immunology literature characterizes naked GQPR and related IgG-hinge peptides (including tuftsin, Thr-Lys-Pro-Arg) as modulators of phagocyte activity and cytokine output in isolated cell systems. This is human-cell data rather than clinical RCT data — foundational biology, not efficacy evidence for a topical anti-aging product.
• IL-6 and skin senescence — The broader literature on IL-6 as a marker and driver of dermal fibroblast senescence (Maggio et al., 2006, PMID 16799139; Franceschi et al., 2018, PMID 30046148) establishes the plausibility of an IL-6-attenuating topical intervention. Plausibility is not efficacy evidence.
• Safety / pharmacovigilance — Rigin / palmitoyl tetrapeptide-7 has been in commercial cosmetic use for roughly two decades in many jurisdictions. Post-market safety signals are minimal — occasional contact sensitization reports of the kind expected for any cosmetic active, no reproducible systemic toxicity signal, no notable regulatory enforcement action. This is reasonable real-world safety reassurance and an honest qualifier on the efficacy uncertainty: the molecule is very unlikely to hurt you, whether or not it reliably does anything measurable.

Dosing from the Literature

Rigin is a topical cosmetic ingredient. Dosing is expressed as percentage of the supplied raw material in a finished formulation. Sederma supplies Rigin as a pre-solubilized glycol-based solution at a fixed active-peptide percentage; finished-product formulation levels below reflect the raw-material inclusion rate, not the isolated peptide content.

→ Use the Kalios Dosing Calculator for topical peptide percentage conversions

Reconstitution & Storage

Rigin is not reconstituted in the sense that a lyophilized research peptide is reconstituted. Sederma supplies the material as a pre-solubilized solution in butylene glycol and water at a fixed active-peptide concentration; the formulator incorporates the solution directly into the aqueous phase of a finished cosmetic product.

• Compatibility — Compatible with glycerin, niacinamide, hyaluronic acid, panthenol, ceramides, most botanical extracts, cosmetic emulsifiers, and most preservatives. Avoid high-concentration ascorbic acid at low pH and benzoyl peroxide in the same phase.
• Preservation — Peptide-containing aqueous formulations require a robust preservative system. Standard cosmetic preservatives (phenoxyethanol / ethylhexylglycerin, benzyl alcohol / dehydroacetic acid blends, or natural alternatives with documented activity) are compatible.
• Heat sensitivity — The peptide fraction is heat-sensitive. Add Rigin at the cool-down phase after emulsion formation, never during the heating phase. Sustained temperatures above 50°C during manufacture measurably degrade peptide content.
• pH sensitivity — Finished-product pH outside 5.0–7.0 progressively degrades the peptide. Formulate within the Sederma recommended range and confirm finished-product pH at batch QC.
• Light and oxygen — Store finished products in light-protected primary packaging (opaque or dark glass / airless pump bottles). Extended exposure to light and oxygen accelerates peptide degradation.
• Not an injectable or research-peptide product — Rigin is a cosmetic raw material. It is not manufactured to injectable-grade specifications and should not be used for parenteral research or self-administration. Lipidated cosmetic peptides are fundamentally different from research peptides intended for subcutaneous injection.

→ Check compound compatibility in the Stack Builder

Side Effects & Risks

Rigin's safety profile as a topical cosmetic active is benign. After approximately two decades of widespread cosmetic use, post-market pharmacovigilance signals are minimal, and the peptide has not been the subject of notable regulatory enforcement in any major jurisdiction.

• Contact sensitization — Rare. Standard cosmetic contact dermatitis mechanisms apply; patch testing in sensitive individuals before full-face use is prudent. The peptide itself is considered a low-sensitization-risk ingredient; adverse reactions in finished products are more commonly attributed to the vehicle, preservatives, or fragrance components than to palmitoyl tetrapeptide-7 directly.
• Comedogenicity — Low at typical inclusion rates. The palmitoyl moiety is a saturated C16 fatty acid, and free palmitic acid has a moderate comedogenic reputation in occlusive formulations. In Rigin the palmitate is covalently bound to the peptide and present at low finished-product concentration, so comedogenic risk is minimal at typical 2–4% raw-material inclusion; very-high-percentage novelty formulations combined with occlusive vehicles theoretically could elevate risk in acne-prone skin.
• No systemic safety data — Rigin has not been evaluated for systemic exposure. It is not indicated, formulated, or labeled for any non-topical route. Cosmetic systemic absorption of a ~692 Da lipidated peptide applied to intact skin is expected to be very low; no pharmacokinetic data at typical use exposure has been published.
• Irritation — Low at typical formulation concentration and pH. Irritation in finished products is more commonly attributable to vehicle components (acids, retinoids, sulfates, essential oils) than to the peptide itself.
• Ocular exposure — Avoid direct eye contact with leave-on formulations; standard cosmetic precaution rather than a peptide-specific warning. Eye-area products containing Rigin are formulated with appropriate pH and preservation for ophthalmically-proximate use.
• Pregnancy and lactation — No specific pregnancy or lactation safety data exist for topical palmitoyl tetrapeptide-7. Given negligible expected systemic absorption, routine cosmetic use is generally considered compatible with pregnancy and lactation, but individuals pregnant or nursing should consult their obstetric care provider for personalized guidance.
• Pediatric use — Rigin is not specifically studied in pediatric populations and is not marketed for that use. Anti-aging cosmetic products are not intended for children or adolescents.
• Drug interactions — Not characterized. Topical cosmetic exposure produces minimal systemic concentration, making clinically meaningful drug interactions extremely unlikely. Routine layering with other topical actives (retinoids, vitamin C, niacinamide, hydroxy acids) is typical and has not generated safety concerns.
• Allergenicity of the IgG-derived sequence — The GQPR sequence is derived from human IgG heavy-chain hinge region. In theory, self-derived peptide sequences should be non-immunogenic in humans; no reported allergenicity signal associated with the GQPR core has emerged in cosmetic pharmacovigilance.
• Regulatory posture — Palmitoyl tetrapeptide-7 is permitted as a cosmetic ingredient under US FDA cosmetic regulation (no pre-market approval required for conventional cosmetic uses) and under EU Cosmetics Regulation EC 1223/2009 (listed cosmetic ingredient, no restrictions noted in Annex II prohibited or Annex III restricted lists at current review).

Bloodwork & Monitoring

Rigin is a topical cosmetic ingredient with negligible expected systemic absorption. No bloodwork or systemic monitoring is indicated for its use. The guidance below is practical for topical-active management generally, not a clinical monitoring protocol.

• No routine bloodwork required — Cosmetic topical use does not warrant routine laboratory evaluation. No metabolic, hepatic, renal, hematologic, hormonal, or inflammatory marker is expected to shift from normal topical use.
• Patch testing before full-face use — Individuals with sensitive skin, a history of cosmetic contact dermatitis, or a preexisting inflammatory dermatosis should apply a small test area on the inner forearm or behind the ear for 48–72 hours before broader application.
• Visual monitoring — Observe treatment areas for erythema, pruritus, urticarial response, or post-inflammatory pigmentation. Discontinue if adverse reaction develops; consult a dermatologist for persistent reactions.
• Photographic tracking — For subjective anti-aging self-evaluation, standardized baseline photographs under consistent lighting at 0, 4, 8, and 12 weeks are more informative than memory-based assessment. Real-world topical cosmetic effect sizes are small and visually gradual.
• Expectation management — Honest topical cosmetic expectations are that measurable improvement in crude wrinkle depth, firmness, or radiance over 8–12 weeks is modest. Any product promising transformation is marketing, not evidence.

Commonly Stacked With

Rigin is a team player rather than a headline peptide. In practice it almost always appears in multi-active topical formulations alongside one or more complementary cosmetic ingredients. The most common pairings:

→ Explore cosmetic peptide layering in the Stack Builder

Regulatory Status

Related Compounds

Cosmetic peptides in the matrikine and cytokine-attenuation class:

Next Steps

Key References

1. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (Foundational cosmetic peptide characterization methodology — reference for the class of acetyl / palmitoyl cosmeceutical peptide assessment.)
2. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The reference independent-style clinical study for a palmitoylated cosmetic peptide — sister compound pal-KTTKS / Matrixyl, not pal-GQPR.)
3. Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836; discussion 836. PMID: 16029675. (Widely cited academic review of the cosmeceutical peptide class including signal peptides, neurotransmitter-acting peptides, and carrier peptides.)
4. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Follow-up review summarizing the three main categories of cosmeceutical peptides with references to Rigin / palmitoyl tetrapeptide-7 class claims.)
5. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (Open-access comprehensive cosmeceutical peptide review covering palmitoyl tetrapeptide-7 / Rigin positioning and IL-6 attenuation claims.)
6. Ferreira MS, Magalhães MC, Sousa Lobo JM, Almeida IF. Trending Anti-Aging Peptides. Cosmetics. 2020;7(4):91. doi:10.3390/cosmetics7040091. (Review of the current cosmetic peptide landscape with detailed discussion of palmitoyl tetrapeptide-7 mechanism claims.)
7. Ferreira MSM, Sousa Lobo JM, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel). 2021;14(8):702. PMID: 34358128. (Review of cosmetic peptide use in sensitive-skin formulations, with mechanistic discussion of palmitoyl tetrapeptide-7's IL-6 attenuation and inflammation-response dampening claims.)
8. Secchi G. Role of protein in cosmetics. Clin Dermatol. 2008;26(4):321-325. PMID: 18691511. (Background on protein and peptide cosmetic ingredient class.)
9. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570043. (Cosmetic peptide topical-delivery review — stratum corneum penetration, palmitoyl conjugate strategy, and mechanism-by-mechanism evidence inventory.)
10. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009;27(5):485-494. PMID: 19695480. (Cosmeceutical peptide review discussing palmitoyl tetrapeptide-7 positioning within the signal / neurotransmitter / carrier peptide framework.)
11. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61(6):575-584. PMID: 16799139. (Foundational review of IL-6 in aging — the biological plausibility case for Rigin's anti-inflammaging positioning.)
12. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. PMID: 30046148. (Inflammaging framework citation — the broader biological context for cosmetic anti-inflammaging peptide claims.)
13. Rocchi R, Biondi L, Filira F, Gobbo M, Dagan S, Fridkin M. Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives. Int J Pept Protein Res. 1987;29(2):250-261. PMID: 3570655. (Classic synthesis and biological characterization of naked tuftsin and rigin tetrapeptides from the IgG hinge region — foundational biology for the Sederma palmitoyl-conjugate product.)
14. Najjar VA, Nishioka K. "Tuftsin": a natural phagocytosis stimulating peptide. Nature. 1970;228(5272):672-673. PMID: 4097539. (Origin-of-the-family reference — the IgG-hinge tuftsin literature that underpins the broader rigin-class biology.)
15. Li H, Colombo I, Tetteh-Quarcoo V, et al. Clinical evidence of the efficacy and safety of a new multi-peptide anti-aging topical eye serum. J Cosmet Dermatol. 2023;22(8):2164-2174. doi:10.1111/jocd.15849. (Representative multi-peptide finished-product clinical evaluation including Matrixyl 3000 [palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7] at 4% — nearest-neighbor human data, combination-only.)
16. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: Influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. PMID: 25433250. (Methodologically adjacent cosmetic peptide skin-penetration study — relevant for the generic topical-delivery case for palmitoylated and acetylated cosmetic peptides.)
17. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. PMID: 8486670. (Origin-of-the-family reference for pal-KTTKS / Matrixyl — the sister palmitoyl cosmetic peptide with which Rigin is routinely combined.)
18. Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. J Cosmet Dermatol. 2009;8(1):8-13. PMID: 19250160. (Cosmetic bioactive peptide overview covering palmitoyl tetrapeptide-7 class and combination formulation logic.)
19. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. PMID: 33195067. (Cosmetic peptide overview referencing palmitoyl tetrapeptide-7 within the broader framework of synthetic cosmetic actives.)
20. Reddy BY, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012;21(8):563-568. PMID: 22672785. (Review of bioactive oligopeptides in dermatology including cosmetic palmitoyl-conjugate peptides.)